 |
| |
| Sep-25-18 | Initiated |
Leerink Partners |
Outperform |
|
|
| Dec-11-17 | Reiterated |
Goldman |
Buy |
$82 → $99 |
|
| Sep-29-17 | Initiated |
BTIG Research |
Buy |
$90 |
|
| Apr-05-17 | Reiterated |
Wedbush |
Outperform |
$43 → $50 |
|
| Mar-13-17 | Upgrade |
Goldman |
Neutral → Buy |
|
|
| Feb-15-17 | Initiated |
Morgan Stanley |
Overweight |
|
|
| Dec-14-16 | Initiated |
Jefferies |
Buy |
$40 |
|
| May-27-16 | Initiated |
Raymond James |
Outperform |
$23 |
|
| May-26-15 | Initiated |
Wedbush |
Outperform |
|
|
| May-26-15 | Initiated |
JMP Securities |
Mkt Outperform |
$54 |
|
| May-26-15 | Initiated |
Goldman |
Neutral |
$26 |
|
|
|
| Jan-07-19 03:47PM | Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today Motley Fool +14.14% |
| 03:06PM | Cancer stocks heat up after third big merger in the past month MarketWatch |
| Jan-04-19 08:00AM | Blueprint Medicines Announces "2020 Blueprint" Global Business Strategy and Outlines Key Corporate Goals PR Newswire +9.82% |
| Dec-17-18 07:20AM | Analysis: Positioning to Benefit within Quidel, Granite Construction, FireEye, Consolidated Edison, EnPro Industries, and Blueprint Medicines Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire |
| Dec-08-18 11:33AM | Is Blueprint Medicines Corporation (BPMC) A Good Stock To Buy? Insider Monkey |
| Dec-04-18 12:14PM | Is Blueprint Medicines Corporations (NASDAQ:BPMC) CEO Overpaid Relative To Its Peers? Simply Wall St. |
| Dec-02-18 12:30PM | Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis PR Newswire |
| Nov-15-18 07:00AM | Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy PR Newswire -6.98% |
| Nov-06-18 03:26PM | Edited Transcript of BPMC earnings conference call or presentation 30-Oct-18 12:30pm GMT Thomson Reuters StreetEvents |
| Nov-05-18 07:40AM | Report: Exploring Fundamental Drivers Behind SkyWest, Blueprint Medicines, HP, Hewlett Packard Enterprise, Cardinal Health, and The Medicines New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
| Oct-30-18 08:50AM | Blueprint Medicines (BPMC) Reports Q3 Loss, Misses Revenue Estimates Zacks |
| 07:44AM | Blueprint Medicines: 3Q Earnings Snapshot Associated Press |
| 07:00AM | Blueprint Medicines Reports Third Quarter 2018 Financial Results PR Newswire |
| Oct-29-18 04:01PM | Blueprint Medicines Strengthens Leadership with the Appointments of Christina Rossi as Chief Commercial Officer and Paul Beresford as General Manager, International PR Newswire -5.82% |
| Oct-23-18 04:01PM | Blueprint Medicines to Report Third Quarter 2018 Financial Results on Tuesday, October 30, 2018 PR Newswire |
| 10:32AM | Blueprint Medicines (BPMC) Q3 Earnings Preview: What to Look Out For Zacks |
| Oct-08-18 08:20AM | Report: Exploring Fundamental Drivers Behind Masonite International, Chart Industries, Blueprint Medicines, Cross Country Healthcare, HNI, and Paylocity Holding New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
| Oct-06-18 08:50AM | Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers PR Newswire |
| Oct-01-18 08:00AM | Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva PR Newswire -5.34% |
| Sep-26-18 08:00AM | Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion PR Newswire |
| Sep-24-18 08:00AM | Blueprint Medicines Showcases Broad Portfolio of Highly Selective Investigational Kinase Medicines with Presentations at Upcoming Medical Meetings PR Newswire |
| Sep-05-18 08:00AM | Blueprint Medicines to Present at 16th Annual Morgan Stanley Global Healthcare Conference PR Newswire |
| Aug-03-18 09:20AM | Edited Transcript of BPMC earnings conference call or presentation 1-Aug-18 12:30pm GMT Thomson Reuters StreetEvents |
| Aug-02-18 06:31AM | What Blueprint Medicines Just Said About Its Future Motley Fool +5.11% |
| Aug-01-18 04:01PM | Blueprint Medicines to Present at Upcoming Investor Conferences in August PR Newswire +12.18% |
| 08:35AM | Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates Zacks |
| 07:34AM | Blueprint Medicines: 2Q Earnings Snapshot Associated Press |
| 07:00AM | Blueprint Medicines Reports Second Quarter 2018 Financial Results PR Newswire |
| 06:30AM | Blueprint Medicines Corp. to Host Earnings Call ACCESSWIRE |
| Jul-25-18 08:00AM | Blueprint Medicines to Report Second Quarter 2018 Financial Results on Wednesday, August 1, 2018 PR Newswire |
| Jun-21-18 08:30AM | New Research: Key Drivers of Growth for Illinois Tool Works, Aircastle, TriState Capital, Blueprint Medicines, MGE Energy, and Cubic Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire |
| 08:00AM | Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stromal Tumors PR Newswire |
| Jun-15-18 08:00AM | Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity PR Newswire -7.29% |
| Jun-06-18 07:40AM | Blog Exposure - Blueprint Medicines Signed Collaboration Deal with CStone Pharma to Develop and Commercialize Avapritinib, BLU-554, and BLU-667 in Greater China ACCESSWIRE -5.23% |
| Jun-04-18 04:23PM | Why #ASCO18 Caused Blueprint Medicines Shares To Tumble Up to 16% Today Motley Fool -9.24% |
| 02:06PM | Blueprint Medicines CEO on genetic targeting for cancer CNBC Videos |
| 07:00AM | Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China PR Newswire |
| Jun-02-18 10:17AM | Loxo Scores A Success With Second Targeted Cancer Drug Forbes |
| Jun-01-18 04:40PM | Conquering cancer in the Windy City CNBC Videos |
| May-31-18 06:01PM | The Big Thing to Watch at ASCO 2018 Motley Fool |
| 08:30AM | Free Technical Insights on CASI Pharma and Three Other Biotech Stocks ACCESSWIRE |
| 08:00AM | Blueprint Medicines to Present at Upcoming Investor Conferences in June PR Newswire |
| May-25-18 03:00AM | Blueprint Medicines Shows Market Leadership With Jump To 93 RS Rating Investor's Business Daily |
| May-24-18 12:41PM | Blueprint CEO traces biotech's rapid growth at opening of new HQ American City Business Journals |
| May-17-18 09:00AM | Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis PR Newswire -5.19% |
| May-07-18 11:55PM | Edited Transcript of BPMC earnings conference call or presentation 2-May-18 12:30pm GMT Thomson Reuters StreetEvents |
| May-02-18 08:24AM | Blueprint Medicines: 1Q Earnings Snapshot Associated Press |
| 07:00AM | Blueprint Medicines Reports First Quarter 2018 Financial Results PR Newswire |
| 06:30AM | Blueprint Medicines Corp. to Host Earnings Call ACCESSWIRE |
| May-01-18 10:34AM | All You Need To Know About Blueprint Medicines Corporations (NASDAQ:BPMC) Financial Health Simply Wall St. |
| 07:55AM | Report: Developing Opportunities within AMC Networks, JELD-WEN Holding, Blueprint Medicines, Northwest Bancshares, Anika Therapeutics, and Aethlon Medical Future Expectations, Projections Moving into 2018 GlobeNewswire |
| Apr-25-18 08:00AM | Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018 PR Newswire |
| Apr-24-18 08:27AM | How Blueprint Medicines Got The Blues Forbes |
| Apr-16-18 12:29PM | Here's Why Blueprint Medicines Fell as Much as 15.1% Today Motley Fool -12.64% |
| Apr-15-18 09:30AM | Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors PR Newswire |
| Mar-19-18 08:30AM | Consolidated Research: 2018 Summary Expectations for Government Properties Income Trust, Grand Canyon Education, The Chefs' Warehouse, Hemispherx BioPharma, Revlon, and Blueprint Medicines Fundamental Analysis, Key Performance Indications GlobeNewswire |
| Mar-14-18 04:35PM | Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018 PR Newswire |
| Mar-06-18 08:00AM | Blueprint Medicines to Present at Cowen and Company 38th Annual Health Care Conference PR Newswire |
| Feb-28-18 07:00AM | Wired News ObsEva Released Positive Top-line Results from IMPLANT2 Phase-3 Clinical Trial Evaluating Nolasiban in IVF ACCESSWIRE |
| Feb-22-18 12:16AM | Edited Transcript of BPMC earnings conference call or presentation 21-Feb-18 1:30pm GMT Thomson Reuters StreetEvents |
| Feb-21-18 11:38AM | Was Blueprint Medicines Corporations (NASDAQ:BPMC) Earnings Decline A Part Of Broader Industry Downturn? Simply Wall St. +6.90% |
| 07:31AM | Blueprint Medicines reports 4Q loss Associated Press |
| 07:01AM | Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results PR Newswire |
| 06:30AM | Blueprint Medicines Corp. to Host Earnings Call ACCESSWIRE |
| Feb-14-18 08:00AM | Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018 PR Newswire +6.35% |
| Jan-09-18 08:15AM | Factors of Influence in 2018, Key Indicators and Opportunity within Barrett Business Services, Tech Data, Approach Resources, ICF International, Blueprint Medicines, and Government Properties Income Trust New Research Emphasizes Economic Growth GlobeNewswire |
| 08:05AM | See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Markit |
| Jan-02-18 08:04AM | See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Markit +6.10% |
| Dec-15-17 04:01PM | Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock PR Newswire |
| Dec-13-17 12:53PM | ETFs with exposure to Blueprint Medicines Corp. : December 13, 2017 Capital Cube |
| Dec-12-17 10:49PM | Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock PR Newswire -7.18% |
| 03:08PM | Goldman Hopes Biotech Investors Keep Singing About These Blues Bloomberg |
| 10:47AM | Company News For Dec 12, 2017 Zacks |
| Dec-11-17 04:31PM | Biotech Stocks Soar On Trial Data At Hematology Conference Investor's Business Daily +22.91% |
| 04:01PM | Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock PR Newswire |
| 10:25AM | Blueprint Medicines Wins Big in Early-Stage Trial 24/7 Wall St. |
| 10:18AM | What does Blueprint Medicines Corporations (BPMC) Balance Sheet Tell Us Abouts Its Future? Simply Wall St. |
| 09:40AM | Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers TheStreet.com |
| Dec-10-17 09:25PM | Cambridge biotechs among big winners at ASH blood disease conference American City Business Journals |
| 08:00AM | Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity PR Newswire |
| Dec-08-17 08:02AM | See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Markit |
| Dec-07-17 02:50PM | Blueprint Medicines Corp. Value Analysis (NASDAQ:BPMC) : December 7, 2017 Capital Cube +6.25% |
| Dec-06-17 07:45AM | Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : December 6, 2017 Capital Cube |
| Nov-30-17 08:03AM | See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Markit +6.38% |
| 06:50AM | Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors PR Newswire |
| Nov-29-17 11:15AM | ETFs with exposure to Blueprint Medicines Corp. : November 29, 2017 Capital Cube |
| Nov-27-17 08:04AM | See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Markit |
| Nov-15-17 08:07AM | See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Markit |
| 07:51AM | Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : November 15, 2017 Capital Cube |
| Nov-14-17 07:50AM | Featured Company News - Blueprint Medicines Announced New Data from Ongoing Phase-1 Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors ACCESSWIRE -7.43% |
| Nov-10-17 09:00AM | Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFR Genotypes PR Newswire |
| Nov-06-17 11:13AM | ETFs with exposure to Blueprint Medicines Corp. : November 6, 2017 Capital Cube -5.10% |
| Nov-03-17 09:55AM | Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube |
| Nov-01-17 04:01PM | Blueprint Medicines Announces Publication of BLU-285 Translational Data PR Newswire +8.10% |
| 09:01AM | Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting and Exposition PR Newswire |
| Oct-31-17 01:56PM | Edited Transcript of BPMC earnings conference call or presentation 31-Oct-17 12:30pm GMT Thomson Reuters StreetEvents |
| 07:28AM | Blueprint Medicines reports 3Q loss Associated Press |
| 07:00AM | Blueprint Medicines Reports Third Quarter 2017 Financial Results PR Newswire |
| Oct-25-17 09:53AM | ETFs with exposure to Blueprint Medicines Corp. : October 25, 2017 Capital Cube |
| Oct-24-17 08:00AM | Blueprint Medicines to Report Third Quarter 2017 Financial Results on Tuesday, October 31, 2017 PR Newswire |
|
|
|
|
| Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, a discovery program targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has an agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Albers Jeffrey W. | CEO and President | Nov 19 | Option Exercise | 1.87 | 28,961 | 54,157 | 28,961 | Nov 21 07:20 AM | | Albers Jeffrey W. | CEO and President | Nov 05 | Option Exercise | 1.87 | 20,000 | 37,400 | 20,000 | Nov 07 04:25 PM | | Albers Jeffrey W. | CEO and President | Nov 05 | Sale | 63.49 | 20,000 | 1,269,709 | 0 | Nov 07 04:25 PM | | Dorsch Marion | Chief Scientific Officer | Sep 17 | Option Exercise | 37.11 | 2,300 | 85,353 | 2,300 | Sep 19 04:08 PM | | Dorsch Marion | Chief Scientific Officer | Sep 17 | Sale | 70.47 | 2,300 | 162,092 | 0 | Sep 19 04:08 PM | | Albers Jeffrey W. | CEO and President | Aug 06 | Option Exercise | 1.87 | 20,000 | 37,400 | 20,000 | Aug 08 04:08 PM | | Albers Jeffrey W. | CEO and President | Aug 06 | Sale | 70.59 | 20,000 | 1,411,896 | 0 | Aug 08 04:08 PM | | Albers Jeffrey W. | CEO and President | May 07 | Option Exercise | 1.87 | 20,000 | 37,400 | 20,000 | May 09 04:29 PM | | Albers Jeffrey W. | CEO and President | May 07 | Sale | 78.90 | 20,000 | 1,578,091 | 0 | May 09 04:29 PM | | Demetri George | Director | Mar 19 | Sale | 100.09 | 5,492 | 549,672 | 6,439 | Mar 21 05:04 PM | | Haviland Kate | Chief Business Officer | Mar 16 | Option Exercise | 28.42 | 4,071 | 115,701 | 9,945 | Mar 20 08:02 PM | | Haviland Kate | Chief Business Officer | Mar 16 | Sale | 100.75 | 4,071 | 410,138 | 5,874 | Mar 20 08:02 PM | | Dorsch Marion | Chief Scientific Officer | Mar 15 | Option Exercise | 37.11 | 2,300 | 85,353 | 2,300 | Mar 19 05:06 PM | | Dorsch Marion | Chief Scientific Officer | Mar 15 | Sale | 100.07 | 2,300 | 230,161 | 0 | Mar 19 05:06 PM | | Albers Jeffrey W. | CEO and President | Mar 02 | Option Exercise | 1.87 | 20,000 | 37,400 | 20,000 | Mar 06 04:55 PM | | Albers Jeffrey W. | CEO and President | Mar 02 | Sale | 92.57 | 20,000 | 1,851,463 | 0 | Mar 06 04:55 PM | | Haviland Kate | Chief Business Officer | Mar 01 | Option Exercise | 36.05 | 2,800 | 100,940 | 8,674 | Mar 05 06:07 PM | | Haviland Kate | Chief Business Officer | Mar 01 | Sale | 90.00 | 2,800 | 252,000 | 5,874 | Mar 05 06:07 PM | | Lydon Nicholas | Director | Feb 28 | Sale | 87.89 | 25,000 | 2,197,356 | 177,727 | Mar 02 05:15 PM | | McCain Tracey L | EVP and Chief Legal Officer | Feb 27 | Option Exercise | 28.36 | 10,000 | 283,600 | 10,000 | Mar 01 05:08 PM | | Haviland Kate | Chief Business Officer | Feb 27 | Option Exercise | 36.05 | 3,200 | 115,360 | 9,074 | Mar 01 05:12 PM | | Haviland Kate | Chief Business Officer | Feb 27 | Sale | 88.20 | 3,200 | 282,236 | 5,874 | Mar 01 05:12 PM | | Demetri George | Director | Feb 27 | Sale | 88.29 | 6,250 | 551,806 | 11,931 | Mar 01 05:06 PM | | McCain Tracey L | EVP and Chief Legal Officer | Feb 27 | Sale | 88.34 | 10,000 | 883,450 | 0 | Mar 01 05:08 PM | | LYNCH DANIEL | Director | Feb 14 | Sale | 80.42 | 12,500 | 1,005,250 | 174,342 | Feb 16 06:52 PM | | Haviland Kate | Chief Business Officer | Feb 12 | Option Exercise | 16.28 | 6,775 | 110,297 | 12,649 | Feb 14 05:23 PM | | LYNCH DANIEL | Director | Feb 12 | Sale | 74.84 | 17,500 | 1,309,668 | 186,842 | Feb 14 05:27 PM | | Haviland Kate | Chief Business Officer | Feb 12 | Sale | 74.93 | 6,775 | 507,619 | 5,874 | Feb 14 05:23 PM |
|
|
|
|
|
|
